The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
무작위 임상시험
4/5 보강
TL;DR
Long-term combination therapy with doxazosin and finasteride was safe and reduced the risk of overall clinical progression of benign prostatic hyperplasia significantly more than did treatment with either drug alone.
📑 코퍼스 인용 관계
· 인용됨 29
📑 인용한 논문 (6) ▾
- Statement from the frontal fibrosing alopecia international expert alliance: SOFFIA 2024. Journal of the European Academy of Dermatology and Venereology : JEADV · 2026
- SRD5A2 and emerging therapies in androgen-driven disorders. Nature reviews. Urology · 2026
- Comparative Effectiveness and Safety of Finasteride and Dutasteride in the Treatment of Be… Medicina (Kaunas, Lithuania) · 2025
- Integrating spatial transcriptomics and single-cell RNA-sequencing reveals epithelial cell… Genes & diseases · 2025
- Change in prostate tissue gene expression following finasteride or doxazosin administratio… Scientific reports · 2024
- A prospective evaluation of the effect of finasteride on prostate health index (phi). International urology and nephrology · 2023
연도별 인용 (2012–2026) · 합계 1,151
OpenAlex 토픽 ·
Urinary Bladder and Prostate Research
Sexual function and dysfunction studies
Urinary Tract Infections Management
Abstract 🌐 Abstract
[BACKGROUND] Benign prostatic hyperplasia is commonly treated with alpha-adrenergic-receptor antagonists (alpha-blockers) or 5alpha-reductase inhibitors. The long-term effect of these drugs, singly or combined, on the risk of clinical progression is unknown.
[METHODS] We conducted a long-term, double-blind trial (mean follow-up, 4.5 years) involving 3047 men to compare the effects of placebo, doxazosin, finasteride, and combination therapy on measures of the clinical progression of benign prostatic hyperplasia.
[RESULTS] The risk of overall clinical progression--defined as an increase above base line of at least 4 points in the American Urological Association symptom score, acute urinary retention, urinary incontinence, renal insufficiency, or recurrent urinary tract infection--was significantly reduced by doxazosin (39 percent risk reduction, P<0.001) and finasteride (34 percent risk reduction, P=0.002), as compared with placebo. The reduction in risk associated with combination therapy (66 percent for the comparison with placebo, P<0.001) was significantly greater than that associated with doxazosin (P<0.001) or finasteride (P<0.001) alone. The risks of acute urinary retention and the need for invasive therapy were significantly reduced by combination therapy (P<0.001) and finasteride (P<0.001) but not by doxazosin. Doxazosin (P<0.001), finasteride (P=0.001), and combination therapy (P<0.001) each resulted in significant improvement in symptom scores, with combination therapy being superior to both doxazosin (P=0.006) and finasteride (P<0.001) alone.
[CONCLUSIONS] Long-term combination therapy with doxazosin and finasteride was safe and reduced the risk of overall clinical progression of benign prostatic hyperplasia significantly more than did treatment with either drug alone. Combination therapy and finasteride alone reduced the long-term risk of acute urinary retention and the need for invasive therapy.
[METHODS] We conducted a long-term, double-blind trial (mean follow-up, 4.5 years) involving 3047 men to compare the effects of placebo, doxazosin, finasteride, and combination therapy on measures of the clinical progression of benign prostatic hyperplasia.
[RESULTS] The risk of overall clinical progression--defined as an increase above base line of at least 4 points in the American Urological Association symptom score, acute urinary retention, urinary incontinence, renal insufficiency, or recurrent urinary tract infection--was significantly reduced by doxazosin (39 percent risk reduction, P<0.001) and finasteride (34 percent risk reduction, P=0.002), as compared with placebo. The reduction in risk associated with combination therapy (66 percent for the comparison with placebo, P<0.001) was significantly greater than that associated with doxazosin (P<0.001) or finasteride (P<0.001) alone. The risks of acute urinary retention and the need for invasive therapy were significantly reduced by combination therapy (P<0.001) and finasteride (P<0.001) but not by doxazosin. Doxazosin (P<0.001), finasteride (P=0.001), and combination therapy (P<0.001) each resulted in significant improvement in symptom scores, with combination therapy being superior to both doxazosin (P=0.006) and finasteride (P<0.001) alone.
[CONCLUSIONS] Long-term combination therapy with doxazosin and finasteride was safe and reduced the risk of overall clinical progression of benign prostatic hyperplasia significantly more than did treatment with either drug alone. Combination therapy and finasteride alone reduced the long-term risk of acute urinary retention and the need for invasive therapy.
- p-value P<0.001
- p-value P=0.002
- 추적기간 4.5 years
Long-term combination therapy with doxazosin and finasteride was safe and reduced the risk of overall clinical progression of benign prostatic hyperplasia significantly more than did treatment with ei
APA 7
McConnell, J. D., Roehrborn, C. G., Bautista, O. M., Andriole, G. L., Dixon, C. M., Kusek, J. W., Lepor, H., McVary, K. T., Nyberg, L. M., Clarke, H. S., Crawford, E. D., Diokno, A., Foley, J. P., Foster, H. E., Jacobs, S. C., Kaplan, S. A., Kreder, K. J., Lieber, M. M., Lucia, M. S., Miller, G. J., & ... (2003). The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.. The New England journal of medicine, 349(25), 2387-98. https://doi.org/10.1056/NEJMoa030656
Vancouver
McConnell JD, Roehrborn CG, Bautista OM, Andriole GL, Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. New Engl. jour. medi.. 2003;349(25):2387-98. doi:10.1056/NEJMoa030656
AMA 11
McConnell JD, Roehrborn CG, Bautista OM, Andriole GL, Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. New Engl. jour. medi.. 2003;349(25):2387-98. doi:10.1056/NEJMoa030656
Chicago
McConnell, J. D., Roehrborn, C. G., Bautista, O. M., Andriole, G. L., Dixon, C. M., Kusek, J. W., Lepor, H., McVary, K. T., Nyberg, L. M., Clarke, H. S., and .... 2003. "The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia." The New England journal of medicine 349 (25): 2387-98. https://doi.org/10.1056/NEJMoa030656
MLA 9
McConnell, J. D., et al. "The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia." The New England journal of medicine, vol. 349, no. 25, 2003, pp. 2387-98. doi:10.1056/NEJMoa030656.
PMID
14681504 ↗
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
인용 관계
그래프 OA 노드: 7/8 (88%)
· 참조 0편 · 후속 7편
이 논문을 인용한 후속 연구 20
- Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?
- Finasteride reduces the risk of incident clinical benign prostatic hyperplasia.
- Finasteride for benign prostatic hyperplasia.
- Dutasteride: a review of current data on a novel dual inhibitor of 5alpha reductase.
- Finasteride and Male Breast Cancer: Does the MHRA Report Show a Link?
- Long-term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial.
- Finasteride treatment and male breast cancer: a register-based cohort study in four Nordic countries…
- Finasteride in the treatment of patients with benign prostatic hyperplasia: a review.
- Comparison of clinical trials with finasteride and dutasteride.
- Combination of tadalafil and finasteride for improving the symptoms of benign prostatic hyperplasia:…
- The effect of 5alpha-reductase inhibition with dutasteride and finasteride on bone mineral density, …
- Evidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment o…
- The effects of dutasteride and finasteride on BPH-related hospitalization, surgery and prostate canc…
- Statement from the frontal fibrosing alopecia international expert alliance: SOFFIA 2024.
- A prospective evaluation of the effect of finasteride on prostate health index (phi).
- Methylated CpG dinucleotides in the 5-α reductase 2 gene may explain finasteride resistance in benig…
- Long-term treatment with finasteride improves clinical progression of benign prostatic hyperplasia i…
- Finasteride monotherapy maintains stable lower urinary tract symptoms in men with benign prostatic h…
- Dutasteride: an evidence-based review of its clinical impact in the treatment of benign prostatic hy…
- SRD5A2 and emerging therapies in androgen-driven disorders.
같은 제1저자의 인용 많은 논문 (5)
- The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.
- Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia.
- Benign prostatic hyperplasia. Hormonal treatment.
- BPH: what really works?
- Benign prostatic hyperplasia: diagnosis and treatment. Agency for Health Care Policy and Research.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- 피나스테리드가 전립선암 발생에 미치는 영향.
- 양성 전립선 비대증 환자에서 finasteride의 효과. The Finasteride Study Group.
- 양성 전립선 비대증 남성에서 급성 요폐의 위험과 수술적 치료 필요성에 대한 finasteride의 효과. Finasteride Long-Term Efficacy and Safety Study Group.
- 양성 전립선 비대증 남성에서 finasteride의 효과.
- 양성 전립선 비대증에서 terazosin, finasteride 또는 병용 요법의 효능. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
- 여성 및 남성 안드로겐성 탈모 치료를 위한 근거기반(S3) 진료지침 - 요약본.